Surfactant therapy: present and future perspectives. Proceedings of the 21st International Workshop on Surfactant Replacement. June 1-4, 2006. Oslo, Norway.

Biol Neonate 2006;89:257–259 258 10 Revak S, Merritt TA, Cochrane CG: Effi cacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996; 39: 715–724. 11 Walther FJ, Gordon LM, Zassadzinski JA, Sherman MA, Waring AJ: Surfactant protein B and C analogues. Mol Genet Metab 2000; 71: 342–351. 12 Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C: Comparative effects of some serum components and proteolytic products of fi brinogen on surface tension-lowering abilities of beractant and a synthetic containing surfactant KL 4 . Pediatr Res 1996; 39: 540– 545. 13 Nutt M, Patel N, Rairkart M, Niven R: Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr Res 2004; 50: 466A. 14 Christofi dou-Solomidou M, Argyris E, Bohen A, Stephens S, Niven R, Segal R: Novel lung surfactant (KL 4 -surfactant) prevents hyperoxic lung injury in mice and decreases neutrophil transmigration in vitro. PAS 2005: 57: 2497. 15 Cochrane CG, Revak SD, Merritt TA, et al: The effi cacy and safety of KL 4 -surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404–410. 16 Moya FR, Gadzinowski J, Bancalari E, et al: A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018–1029. 17 Sinha SK, Lacaze-Masmonteil T, Soler AV, et al: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030–1038.